Search

Displaying results 6931 - 6940 of 10000 in total
  1. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. … Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer

  2. Drug

    Ferric subsulfate

    go.drugbank.com/drugs/DB13885
    Approved

    Ferric subsulfate is a stypic or hemostatic agent that causes agglutination of surface proteins resulting in local hemostasis. It has the chemical formula Fe4(OH)2(SO4)5.

  3. Drug

    Zirconium dioxide

    go.drugbank.com/drugs/DB16552
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    2,5-Dimethoxy-4-ethylamphetamine

    go.drugbank.com/drugs/DB01467
    ExperimentalIllicit

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Afelimomab

    go.drugbank.com/drugs/DB04956
    Experimental

    Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.

  6. Drug

    4-nitrophenyl-beta-D-galactoside

    go.drugbank.com/drugs/DB02632
    Experimental

    Categories: Compounds used in a research, industrial, or household settingSynonyms: 1-O-(4-nitrophenyl)-β-D-galactose, 1-O-(p-nitrophenyl)-β-D-galactose
  7. Drug

    IN01

    go.drugbank.com/drugs/DB16434
    Experimental

    The IN01 Vaccine, sponsored by the Instituto Oncologico Dr Rosell, IN3BIO, and PANGAEA, is a compound containing recombinant bacteria[L30543]. … Of note, the IN01 vaccine is being tested in a Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 infection (NCT04537130).

  8. Drug

    Dihydrostreptomycin

    go.drugbank.com/drugs/DB11512
    ApprovedVet approvedWithdrawn

    Dihydrostreptomycin is an aminoglycoside antibiotic. In humans, the use of dihydrostreptomycin has been associated with ototoxicity. … The FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin sulfate.[L43942]

    Synonyms: N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-a-L-glucopyranosyl]-3-C-(hydroxymethyl)-a-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine, N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-α-L-glucopyranosyl]-3-C-(hydroxymethyl)-α-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine
  9. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    ) and on other risk factors such as hypertension or diabetes. … GFT14 is a new class of medicaction for treatment of cardiometabolic disease.

  10. Drug

    AI-850

    go.drugbank.com/drugs/DB05842
    Experimental

    AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.